Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Mol Biol Cell ; 18(10): 4003-12, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17686994

RESUMEN

Synovial sarcoma is a soft tissue cancer associated with a recurrent t(X:18) translocation that generates one of two fusion proteins, SYT-SSX1 or SYT-SSX2. In this study, we demonstrate that SYT-SSX2 is a unique oncogene. Rather than confer enhanced proliferation on its target cells, SYT-SSX2 instead causes a profound alteration of their architecture. This aberrant morphology included elongation of the cell body and formation of neurite-like extensions. We also observed that cells transduced with SYT-SSX2 often repulsed one another. Notably, cell repulsion is a known component of ephrin signaling. Further analysis of SYT-SSX2-infected cells revealed significant increases in the expression and activation of Eph/ephrin pathway components. On blockade of EphB2 signaling SYT-SSX2 infectants demonstrated significant reversion of the aberrant cytoskeletal phenotype. In addition, we discovered, in parallel, that SYT-SSX2 induced stabilization of the microtubule network accompanied by accumulation of detyrosinated Glu tubulin and nocodazole resistance. Glu tubulin regulation was independent of ephrin signaling. The clinical relevance of these studies was confirmed by abundant expression of both EphB2 and Glu tubulin in SYT-SSX2-positive synovial sarcoma tissues. These results indicate that SYT-SSX2 exerts part of its oncogenic effect by altering cytoskeletal architecture in an Eph-dependent manner and cytoskeletal stability through a concurrent and distinct pathway.


Asunto(s)
Citoesqueleto/metabolismo , Efrinas/metabolismo , Proteínas de Fusión Oncogénica/metabolismo , Sarcoma Sinovial/metabolismo , Animales , Proliferación Celular/efectos de los fármacos , Forma de la Célula/efectos de los fármacos , Citoesqueleto/efectos de los fármacos , Activación Enzimática/efectos de los fármacos , Efrinas/genética , Regulación de la Expresión Génica/efectos de los fármacos , Ratones , Microtúbulos/efectos de los fármacos , Microtúbulos/metabolismo , Células 3T3 NIH , ARN Mensajero/genética , ARN Mensajero/metabolismo , Receptor EphB2/metabolismo , Retroviridae/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , Tirfostinos/farmacología
2.
Wound Repair Regen ; 16(3): 442-9, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18282264

RESUMEN

MRL/MpJ-Fas(lpr) mice exhibit the ability to regenerate ear tissue excised by dermal punches. This is an exceptional model to identify candidate proteins that may regulate regeneration in typically nonregenerative tissues. Identification of key molecules involved in regeneration can broaden our understanding of the wound-healing process and generate novel therapeutic approaches. Tissue profiling by matrix-assisted laser desorption ionization mass spectrometry is a rapid, powerful proteomic tool that allows hundreds of proteins to be detected from specific regions of intact tissue specimens. To identify these candidate molecules, protein expression in ear punches was examined after 4 and 7 days using tissue profiling of MRL/MpJ-Fas(lpr) mice and the nonregenerative mouse strain C57BL/6J. Spectral analysis revealed distinct proteomic differences between the regenerative and nonregenerative phenotypes, including the calcium-binding proteins calgranulin A and B, calgizzarin, and calmodulin. Spatial distributions for these differentially expressed proteins within the injured regions were confirmed by immunohistochemistry.


Asunto(s)
Proteínas de Unión al Calcio/análisis , Expresión Génica , Proteoma/química , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Cicatrización de Heridas/genética , Animales , Oído Externo/lesiones , Ratones , Ratones Endogámicos , Proteoma/genética , Piel/lesiones , Fenómenos Fisiológicos de la Piel/genética , Fenómenos Fisiológicos de la Piel/inmunología , Cicatrización de Heridas/inmunología
3.
J Leukoc Biol ; 79(1): 192-201, 2006 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-16282533

RESUMEN

The bone morphogenetic protein receptor-2 (BMPR2) is a member of the transforming growth factor-beta receptor family and is expressed on the surface of several cell types including endothelial cells and macrophages. Recently, a cause for familial primary pulmonary hypertension (FPPH) has been identified as mutations in the gene encoding BMPR2. Three forms of pulmonary hypertension (PH) exist, including PPH, FPPH, and PH secondary to other etiologies (sporadic PH) such as drug abuse and human immunodeficiency virus (HIV) infection. It is interesting that these subtypes are histologically indistinguishable. The macrophage is a key target cell for HIV-1, significantly altering macrophage cell function upon infection. HIV-1 trans-activator of transcription (Tat), an immediate-early product of the HIV-1 lifecycle, plays an important role in mediating HIV-induced modulation of host cell function. Our laboratory has previously shown that Tat represses mannose receptor transcription in macrophages. In the current study, we examined activity from the BMPR2 promoter in the macrophage cell line U937 and potential regulation by Tat. Transfection of U937 cells with BMPR2 promoter-reporter constructs revealed dose-dependent repression of BMPR2 promoter activity in the presence of Tat. Experiments using truncations of the BMPR2 promoter localized Tat-mediated repression to the first 208 bases of the promoter. Decreased BMPR2 transcription resulted in altered downstream signaling. Similar to mothers against decapentaplegics (SMAD) phosphorylation and SMAD6 expression, in response to BMP2 treatment, were down-regulated after Tat treatment. Finally, HIV-1 infection and treatment with Tat protein of the U937 human monocytic cell line resulted in a decreased, endogenous BMPR2 transcript copy number.


Asunto(s)
Receptores de Proteínas Morfogenéticas Óseas de Tipo II/biosíntesis , Regulación hacia Abajo , Productos del Gen tat/metabolismo , Infecciones por VIH/metabolismo , VIH-1 , Transducción de Señal , Receptores de Proteínas Morfogenéticas Óseas de Tipo II/genética , Células Endoteliales/metabolismo , Productos del Gen tat/farmacología , Infecciones por VIH/genética , Humanos , Hipertensión Pulmonar/genética , Lectinas Tipo C/biosíntesis , Lectinas Tipo C/genética , Macrófagos/metabolismo , Macrófagos/virología , Receptor de Manosa , Lectinas de Unión a Manosa/biosíntesis , Lectinas de Unión a Manosa/genética , Mutación , Fosforilación , Procesamiento Proteico-Postraduccional , Receptores de Superficie Celular/biosíntesis , Receptores de Superficie Celular/genética , Elementos de Respuesta/genética , Proteína smad6/biosíntesis , Proteína smad6/genética , Células U937 , Productos del Gen tat del Virus de la Inmunodeficiencia Humana
4.
Cancer Res ; 64(24): 9093-100, 2004 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-15604278

RESUMEN

Biomarkers that predict therapeutic response are essential for the development of anticancer therapies. We have used matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) to directly analyze protein profiles in mouse mammary tumor virus/HER2 transgenic mouse frozen tumor sections after treatment with the erbB receptor inhibitors OSI-774 and Herceptin. Inhibition of tumor cell proliferation and induction of apoptosis and tumor reduction were predicted by a >80% reduction in thymosin beta4 and ubiquitin levels that were detectable after 16 hours of a single drug dose before any evidence of in situ cellular activity. These effects were time- and dose-dependent, and their spatial distribution in the tumor correlated with that of the small-molecule inhibitor OSI-774. In addition, they predicted for therapeutic synergy of OSI-774 and Herceptin as well as for drug resistance. These results suggest that drug-induced early proteomic changes as measured by MALDI-MS can be used to predict the therapeutic response to established and novel therapies.


Asunto(s)
Anticuerpos Monoclonales/farmacología , Biomarcadores de Tumor/metabolismo , Neoplasias Mamarias Experimentales/tratamiento farmacológico , Neoplasias Mamarias Experimentales/metabolismo , Proteoma/metabolismo , Quinazolinas/farmacología , Secuencia de Aminoácidos , Animales , Anticuerpos Monoclonales/farmacocinética , Anticuerpos Monoclonales Humanizados , Sinergismo Farmacológico , Receptores ErbB/antagonistas & inhibidores , Clorhidrato de Erlotinib , Femenino , Humanos , Ratones , Ratones Transgénicos , Datos de Secuencia Molecular , Valor Predictivo de las Pruebas , Inhibidores de Proteínas Quinasas/farmacocinética , Inhibidores de Proteínas Quinasas/farmacología , Quinazolinas/farmacocinética , Receptor ErbB-2/antagonistas & inhibidores , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Trastuzumab
5.
Clin Orthop Relat Res ; 450: 105-10, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16906088

RESUMEN

UNLABELLED: Proteomics is the emerging technology that evaluates normal and abnormal protein expression in tissues. Tissue profiling by matrix assisted laser desorption ionization mass spectrometry (MALDI MS) is a proteomic tool that permits the rapid detection of proteins expressed in tissues and serum. To date, tissue profiling has been successfully utilized to detect proteins specific to various cancers, including those of non-small cell lung carcinoma and glioblastoma multiforme. The usefulness of histological analyses to predict soft tissue sarcoma (STS) behavior has plateaued, and a critical need exists to identify other means to objectively predict tumor grade and behavior. We describe tissue profiling as a tool for orthopaedic research, and review recent work utilizing the technology for detecting proteins that differentiate low grade from high grade STS. We used MALDI MS tissue profiling technology to detect differentially expressed proteins in high grade and low grade STS. LEVEL OF EVIDENCE: Level I, prognostic study.


Asunto(s)
Análisis por Matrices de Proteínas/métodos , Sarcoma/metabolismo , Neoplasias de los Tejidos Blandos/metabolismo , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Proteínas de Ciclo Celular/metabolismo , Humanos , Inmunohistoquímica , Proteína A6 de Unión a Calcio de la Familia S100 , Proteínas S100/metabolismo , Sarcoma/patología , Neoplasias de los Tejidos Blandos/patología
6.
Arch Biochem Biophys ; 449(1-2): 27-33, 2006 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-16615932

RESUMEN

Macrophage transcription is significantly altered by HIV-1 infection. HIV Tat, an immediate-early product of the viral lifecycle, interacts with host transcription factors to alter host gene expression. We have previously shown that Tat represses transcription from the mannose receptor (MR) and the bone morphogenetic protein receptor-2 (BMPR2) promoters. The current study shows that transcriptional repression of these receptors involves Tat interaction with cyclin T1. Assays using U937 human monocytic cells transiently expressing MR or BMPR2 promoter-luciferase constructs demonstrated equal repression by one- and two-exon Tat gene products. A mutant Tat expression vector encoding Tat protein lacking the cyclin T1 binding domain failed to inhibit MR and BMPR2 promoter activities. Over-expression of cyclin T1 in the presence of wild-type Tat resulted in recovered activity from both promoters. Finally, two inhibitors of cyclin-dependent kinase 9 (a dominant negative CDK9 and flavopiridol) repressed activity from the MR and BMPR2 promoters.


Asunto(s)
Receptores de Proteínas Morfogenéticas Óseas de Tipo II/metabolismo , Proteínas Morfogenéticas Óseas/metabolismo , Ciclinas/metabolismo , Histona Acetiltransferasas/metabolismo , Monocitos/metabolismo , Activación Transcripcional/fisiología , Factor de Crecimiento Transformador beta/metabolismo , Sitios de Unión , Proteína Morfogenética Ósea 2 , Receptores de Proteínas Morfogenéticas Óseas de Tipo II/genética , Proteínas Morfogenéticas Óseas/genética , Línea Celular , Ciclina T , Humanos , Lectinas Tipo C/genética , Lectinas Tipo C/metabolismo , Lisina Acetiltransferasa 5 , Receptor de Manosa , Lectinas de Unión a Manosa/genética , Lectinas de Unión a Manosa/metabolismo , Unión Proteica , Receptores de Superficie Celular/genética , Receptores de Superficie Celular/metabolismo , Factor de Crecimiento Transformador beta/genética
7.
J Investig Dermatol Symp Proc ; 11(1): 132-9, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17069021

RESUMEN

Mechanisms that drive wound repair are complex and have challenged wound-healing investigators for many years. In this review, we present four examples of new tools that are being utilized to discover events that drive wound repair and regeneration. Laser capture microdissection facilitates the focused collection of tissue for purposes of genomic or proteomic analysis from specific cell populations within the wound bed. Tissue profiling and protein imaging by matrix-assisted laser desorption ionization mass spectrometry are two proteomic-based tools that permit rapid analysis with spatial orientation and relative abundance of hundreds to thousands of molecules from intact tissues. Another approach uses an in vivo porcine model to harness a strategy of adenoviral-driven receptor overexpression. This biological model closely mimics the human setting and permits transient stimulation along a specific cytokine pathway to tip the balance in favor of accelerated repair. The advent of new approaches that collect cell samples from within their in vivo circumstance while preserving discrete cellular localizations is likely to move the field of wound repair forward.


Asunto(s)
Cicatrización de Heridas/fisiología , Adenoviridae/genética , Animales , Quemaduras/metabolismo , Quemaduras/patología , Factor de Crecimiento Epidérmico/metabolismo , Receptores ErbB/genética , Humanos , Microdisección , Receptor ErbB-4 , Regeneración , Transducción de Señal , Fenómenos Fisiológicos de la Piel , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción
8.
Mol Cell Proteomics ; 4(4): 394-401, 2005 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-15677390

RESUMEN

Matrix-assisted laser desorption ionization mass spectrometry (MALDI MS) has become a valuable tool to address a broad range of questions in many areas of biomedical research. One such application allows spectra to be obtained directly from intact tissues, termed "profiling" (low resolution) and "imaging" (high resolution). In light of the fact that MALDI tissue profiling allows over a thousand peptides and proteins to be rapidly detected from a variety of tissues, its application to disease processes is of special interest. For example, protein profiles from tumors may allow accurate prediction of tumor behavior, diagnosis, and prognosis and uncover etiologies underlying idiopathic diseases. MALDI MS, in conjunction with laser capture microdissection, is able to produce protein expression profiles from a relatively small number of cells from specific regions of heterogeneous tissue architectures. Imaging mass spectrometry enables the investigator to assess the spatial distribution of proteins, drugs, and their metabolites in intact tissues. This article provides an overview of several tissue profiling and imaging applications performed by MALDI MS, including sample preparation, matrix selection and application, histological staining prior to MALDI analysis, tissue profiling, imaging, and data analysis. Several applications represent direct translation of this technology to clinically relevant problems.


Asunto(s)
Espectrometría de Masas/métodos , Animales , Humanos , Rayos Láser , Microdisección , Péptidos/análisis , Péptidos/química , Análisis por Matrices de Proteínas , Proteínas/análisis , Proteínas/química , Espectrometría de Masa por Ionización de Electrospray , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Distribución Tisular
9.
Cancer Genomics Proteomics ; 2(6): 333-345, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-31394650

RESUMEN

Soft tissue sarcomas are rare, heterogeneous, mesenchymal tumors that have been poorly classified. The heterogeneity of these aggressive tumors has made consistent tumor grading difficult and accurately predicting the behavior of the tumor based on the histological subtype and grade has been challenging. Molecular profiling of proteins in tissues may present a new avenue for distinguishing clinical grades and overall tumor aggressiveness. Direct tissue analysis using matrix-assisted laser desorption ionization mass spectrometry is a new technology that permits rapid detection of hundreds of proteins from intact tissues. We have employed this technology to profile human soft tissue sarcomas to discover protein biomarkers that distinguish tumor grade. Profiling was accomplished on histologically-stained tissue sections, allowing highly reproducible spectra for each sarcoma grade to be obtained. Forty-two tissue specimens were analyzed in this manner. Several proteins specific for high-grade sarcomas were identified and confirmed with immunohistochemistry. Proteins present in control tissue, that are suppressed by soft tissue sarcomas, were also identified.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA